Фармакоэкономическая эффективность атипичных антипсихотиков у больных шизофренией
Аннотация
Проведён сравнительный фармакоэкономический анализ применения атипичных антипсихотиков у больных шизофренией.
Об авторах
Ю. Б. Белоусов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Россия
Россия
д.м.н., проф., зав. кафедрой клинической фармакологии с курсом клинической фармакологии и фармакокинетики ФУВ
Д. Ю. Белоусов
http://www.healtheconomics.ru/
ООО "Центр фармакоэкономических исследований", г. Москва
Россия
ООО "Центр фармакоэкономических исследований", г. Москва
Россия
генеральный директор
SPIN-код: 6067-9067
В. В. Омельяновский
Российский государственный медицинский университет, г. Москва
Россия
Россия
Список литературы
1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154 Suppl. 4: 1-63.
2. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158: 518-26.
3. Davis J.M., Chen N., Glick I.D. A metaanalysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64.
4. Davis J.M., Matalon L., Watanabe M.D., et al. Depot antipsychotic drugs: place in therapy. Drugs 1994 May; 47 (5): 741-73.
5. Duncan J.C., Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998 Nov; 46 (3): 1133-7.
6. Edwards N., Locklear J., Rupnow M., Diamond R., et al. Cost-effectiveness evaluation of long-acting risperidone. Poster presentation for Financing Mental and Addictive Disorders; Venice, Italy, Scuola Grande di San Giovanni Evangelista, March 18-20, 2005.
7. Edwards N., Rupnow M., Locklear J., et al. Cost-effectiveness evaluation of long-acting risperidone. [Poster] Presented at ISPOR 9th Annual International Meeting. May 2004, Washington, D.C.
8. Edwards N., Rupnow M., Pashos C., et al. Cost-effectiveness evaluation of long-acting risperidone. Pharmacoeconomics 2005: 23 (3): 299-314.
9. Ereshefsky L., Saklad S.R., Jann M.W., et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984 May; 45 (5 Pt 2): 50-9.
10. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321: 1371-6.
11. Glazer W.M., Kane J.M. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992 Dec; 53 (12): 426-33.
12. Hogarty G.E., Anderson C.M., Reiss D.J., et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch Gen Psychiatry 1991 Apr; 48 (4): 340-7.
13. Hogarty G.E., Schooler N.R., Ulrich R., et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a wo-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979 Nov; 36 (12): 1283-94.
14. Johnson D.A., Pasterski G., Ludlow J.M., et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983 May; 67 (5): 339-52.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
16. Kelly G.R., Scott J.E., Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990 Dec; 28 (12): 1181-97.
17. Kendler K.S., Gallagher T.J., Abelson J.M., et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry 1996 Nov; 53 (11): 1022-31.
18. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1997; 89 Suppl. 382: 16-24.
19. Lehman A.F., Steinwachs D.M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24 (1): 1-10.
20. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-22.
21. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35: 51-68.
22. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Эффективность антипсихотических препаратов у больных хронической шизофренией. Расширенный реферат с комментариями С.Н. Мосолова//Терапия психических расстройств. №1. 2006.(http://www.psychiatry-therapy.ru/archive/n1-2006/n1-2006_160.html).
24. Miller A.L., Chiles J.A., Chiles J.K., et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999 Oct; 60 (10): 649-57.
25. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10: 79-104.
26. Olivares J.M., Rodriguez A., Povey M., Diels J, Jacobs A on behalf of the e-STAR study group. 6-month follow-up from the electronic-Schizophrenia Adherence Treatment Registry (e-STAR) of patients in Spain who were initiated to Risperidone Long-Acting Injection (RLAI).//9th ISPOR European Congress, Copenhagen, Denmark, 28-31 October 2006. e-STAR Spain cohort, Draft 1, 09 June 06.
27. Rosenheck R., Perlick D., Bingham S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290: 2693-702.
28. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study, II: treatment: pimozide versus flupenthixol. Br J Psychiatry 1987 Mar; 150: 334-8.
29. Tollefson G.D., Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidolcontrolled clinical trial with olanzapine. Am J Psychiatry 1997;154: 466-74.
30. Tuunainen A., Wahlbeck K., Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56: 1-10.
31. Wahlbeck K., Cheine M., Essali A., Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156: 990-9.
32. Weiden P.J., Dixon L., Frances A., et al. Neuroleptic noncompliance in schizophrenia. In: Tamming CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology: schizophrenia research. Vol. 1, New York: Raven Press, 1991: 285-96.
33. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29.
34. http://www.medlux.ru/ от 20.01.2007 г.
35. Young J.L., Zonana H.V., Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14 (2): 105-22.
36. Yousef H.A. A five-year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanoate versus other neuroleptics. Adv Ther 1989; 67: 186-95.
37. Зозуля Т.В. Эпидемиологическое исследование психически больных пожилого и старческого возраста и вопросы организации медико-социальной помощи: Автореф. дис.... д-ра мед.наук. Москва, 1998.
38. Прейскурант на оказание медицинских услуг клиники Научного центра психического здоровья РАМН. Москва, 2006 г.
39. Прейскурант на оказании медицинских услуг больницы им. Боткина, 2006 г.
40. Рытик Э.Г. Разработка клинико-статистических групп для оценки деятельности психиатрических стационаров: Автореф. дис.... д-ра мед.наук. Москва, 1993.
41. Стандарты оказания помощи больным шизофренией. Московский НИИ психиатрии Росздрава./Под редакцией В.Н.Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера. Москва, 2006 г.
42. Краснов С.Ю. Новые Санкт-Петербургские ведомости. 2004. № 4. С. 16-18.
43. Rossler W., Salize H.J., van Os J., Riecher-Rossler A. Бремя шизофрении и психотических расстройств в странах Евросоюза (расширенный реферат)//Психиатрия и фармакотерапия. 2006. Т. 11, № 2.
44. Fleishhacker W.W., Eerdeckens M., Karcher K., et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 Oct; 64 (10): 1250-7.
Рецензия
Для цитирования:
Белоусов Ю.Б., Белоусов Д.Ю., Омельяновский В.В. Фармакоэкономическая эффективность атипичных антипсихотиков у больных шизофренией. Качественная Клиническая Практика. 2006;(2):60-71.
Просмотров: 2305
Послать статью по эл. почте 